Next Article in Journal
Reducing Low Birth Weight among African Americans in the Midwest: A Look at How Faith-Based Organizations Are Poised to Inform and Influence Health Communication on the Developmental Origins of Health and Disease (DOHaD)
Next Article in Special Issue
Socio-Demographic Determinants of Diet Quality in Australian Adults Using the Validated Healthy Eating Index for Australian Adults (HEIFA-2013)
Previous Article in Journal
Brazilian Specialists’ Perspectives on the Patient Referral Process
Previous Article in Special Issue
Effectiveness of a Lifestyle Intervention in Patients with Type 2 Diabetes: The Physical Activity and Nutrition for Diabetes in Alberta (PANDA) Trial

The Role of Lipid Biomarkers in Major Depression

Basic and Clinical Neuroscience, Institute of Psychology, Psychiatry and Neuroscience, King’s College London, 125 Coldharbour Lane, London SE5 9NU, UK
Author to whom correspondence should be addressed.
Academic Editor: Sampath Parthasarathy
Healthcare 2017, 5(1), 5;
Received: 28 October 2016 / Revised: 20 January 2017 / Accepted: 23 January 2017 / Published: 3 February 2017
(This article belongs to the Special Issue Diet Quality)
In the UK, the lifetime-documented prevalence of major depressive disorder (MDD) is currently 10%. Despite its increasing prevalence and devastating impact on quality of life, the pathophysiological mechanisms underpinning MDD remain to be fully elucidated. Current theories of neurobiological components remain incomplete and protein-centric, rendering pharmacological treatment options suboptimal. In this review, we highlight the pivotal role of lipids in intra- and inter-neuronal functioning, emphasising the potential use of lipids as biomarkers for MDD. The latter has significant implications for improving our understanding of MDD at the cellular and circuit level. There is particular focus on cholesterol (high and low density lipoprotein), omega-3, and omega-6 polyunsaturated fatty acids due to established evidence in the literature of a link between atherosclerotic disease and major depression. We argue that there is significant potential scope for the use of such peripheral biomarkers in the diagnosis, stratification and treatment of MDD. View Full-Text
Keywords: lipid biomarkers; major depressive disorder; cholesterol; polyunsaturated fatty acids lipid biomarkers; major depressive disorder; cholesterol; polyunsaturated fatty acids
Show Figures

Figure 1

MDPI and ACS Style

Parekh, A.; Smeeth, D.; Milner, Y.; Thuret, S. The Role of Lipid Biomarkers in Major Depression. Healthcare 2017, 5, 5.

AMA Style

Parekh A, Smeeth D, Milner Y, Thuret S. The Role of Lipid Biomarkers in Major Depression. Healthcare. 2017; 5(1):5.

Chicago/Turabian Style

Parekh, Amy, Demelza Smeeth, Yasmin Milner, and Sandrine Thuret. 2017. "The Role of Lipid Biomarkers in Major Depression" Healthcare 5, no. 1: 5.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop